CAJ | 학술논문

　　在世界范围内，肺癌位居所有癌症致死的首位，且其中大部分为非小细胞肺癌。尽管大量有关含铂化疗或联合其他药物的临床研究不断涌现，非小细胞肺癌患者的预后仍然差强人意。晚期非小细胞肺癌患者的5年生存率约为15％，在过去几年中未有明显提高。目前，肺癌治疗领域的主要成就在于靶向治疗的出现，例如针对表皮生长因子受体(EGFR)靶点的吉非替尼和厄罗替尼，以及针对抗血管内皮生长因子(VEGF)的贝伐珠单抗，均广泛运用于临床。
　　재세계범위내，폐암위거소유암증치사적수위，차기중대부분위비소세포폐암。진관대량유관함박화료혹연합기타약물적림상연구불단용현，비소세포폐암환자적예후잉연차강인의。만기비소세포폐암환자적5년생존솔약위15％，재과거궤년중미유명현제고。목전，폐암치료영역적주요성취재우파향치료적출현，례여침대표피생장인자수체(EGFR)파점적길비체니화액라체니，이급침대항혈관내피생장인자(VEGF)적패벌주단항，균엄범운용우림상。
Lung cancer continues to be the leading cause of cancer death worldwide,and non-smal cel lung cancer is the most common lung cancers.Despite many clinical trials of platinum-based chemotherapy in combination with various drugs,the median survival of patients with non-smal cel lung cancer remains poor.The overal 5-year survival rate of the patients is approximately 15%,and has improved only marginal y in recent years.A recent milestone in this field has been the development of molecular-targeting drugs,among which gefitinib and erlotinib targeting the epidermal growth factor receptor (EGFR) have improved the efficacy for non-smal cel lung cancer. Anti-angiogenetic drug, such as bevacizumab,has been used to treat non-smal cel lung cancer.